Replimune Group, Inc.: Form 10-Q for the period ended Dec 31, 2019
Filed with the SEC on Feb 13, 2020 and accepted by EDGAR at Feb 13, 2020, 11:31 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2019-10-01 to 2019-12-31 | $11.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2019-04-01 to 2019-12-31 | $27.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-10-01 to 2019-12-31 | −$16.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2019-04-01 to 2019-12-31 | −$39.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-10-01 to 2019-12-31 | $834.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2019-04-01 to 2019-12-31 | $1.0m | us-gaap:InterestExpense |
| Net income | 3 months2019-10-01 to 2019-12-31 | −$16.2m | us-gaap:NetIncomeLoss |
| Net income | 9 months2019-04-01 to 2019-12-31 | −$36.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-10-01 to 2019-12-31 | −$0.46 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2019-04-01 to 2019-12-31 | −$1.13 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2019-04-01 to 2019-12-31 | −$49.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2019-04-01 to 2019-12-31 | $5.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-12-31 | $63.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-12-31 | $190.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-12-31 | $250.4m | us-gaap:Assets |
| Current liabilities | At period end2019-12-31 | $14.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-12-31 | $52.9m | us-gaap:Liabilities |
| Long-term debt | At period end2019-12-31 | $9.7m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2019-12-31 | $197.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-20-019880. Last ingested by Listed: Nov 3, 2026, 23:32 ET. Listed shows no prices and gives no investment advice.